Patents by Inventor Elena Burova
Elena Burova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10358495Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: October 7, 2016Date of Patent: July 23, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
-
Patent number: 10306874Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: November 18, 2016Date of Patent: June 4, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
-
Publication number: 20190048096Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: July 26, 2018Publication date: February 14, 2019Inventors: Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON, William OLSON
-
Publication number: 20180236070Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.Type: ApplicationFiled: April 23, 2018Publication date: August 23, 2018Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ella IOFFE, Israel LOWY, Gavin THURSTON, Elena BUROVA
-
Publication number: 20180206462Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: March 20, 2018Publication date: July 26, 2018Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20180186883Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: February 26, 2018Publication date: July 5, 2018Inventors: Nicholas J. PAPADOPOULOS, Andrew J. MURPHY, Gavin THURSTON, Ella IOFFE, Elena BUROVA
-
Publication number: 20180185668Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: ApplicationFiled: February 26, 2018Publication date: July 5, 2018Inventors: Nicholas J. PAPADOPOULOS, Andrew J. MURPHY, Gavin THURSTON, Ella IOFFE, Elena BUROVA
-
Publication number: 20180160663Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: January 30, 2018Publication date: June 14, 2018Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Patent number: 9987500Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: GrantFiled: January 23, 2015Date of Patent: June 5, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 9968674Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.Type: GrantFiled: October 17, 2014Date of Patent: May 15, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ella Ioffe, Israel Lowy, Gavin Thurston, Elena Burova
-
Patent number: 9955677Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: June 19, 2015Date of Patent: May 1, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
-
Patent number: 9938345Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: GrantFiled: January 23, 2015Date of Patent: April 10, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Patent number: 9913461Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: December 9, 2015Date of Patent: March 13, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20170142943Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that said non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: November 18, 2016Publication date: May 25, 2017Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
-
Publication number: 20170101472Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: October 7, 2016Publication date: April 13, 2017Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON
-
Publication number: 20160243225Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.Type: ApplicationFiled: October 17, 2014Publication date: August 25, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ella IOFFE, Israel LOWY, Gavin THURSTON, Elena BUROVA
-
Publication number: 20160157469Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: December 9, 2015Publication date: June 9, 2016Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
-
Publication number: 20150366174Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Pdcd1 gene so that said non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: ApplicationFiled: June 19, 2015Publication date: December 24, 2015Inventors: Elena BUROVA, Alexander O. MUJICA, Ka-Man Venus LAI, Andrew J. MURPHY
-
Publication number: 20150203580Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: January 23, 2015Publication date: July 23, 2015Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
-
Publication number: 20150203579Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.Type: ApplicationFiled: January 23, 2015Publication date: July 23, 2015Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova